Alnylam Pharmaceuticals Inc (ALNY) — Cash Flow Reinvestment Rate
Alnylam Pharmaceuticals Inc (ALNY) has a Cash Flow Reinvestment Rate of 0.23x as of December 2025, reinvesting $37.17 Million (capex $23.29 Million plus investments $-13.87 Million) from operating cash flow of $163.56 Million. See Alnylam Pharmaceuticals Inc free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Alnylam Pharmaceuticals Inc Cash Flow Reinvestment Rate (2007–2025)
Historical reinvestment intensity for Alnylam Pharmaceuticals Inc across 4 annual periods. For the full cash flow conversion analysis, see Alnylam Pharmaceuticals Inc cash conversion from operations.
Annual Cash Flow Reinvestment Rate for Alnylam Pharmaceuticals Inc (2007–2025)
Year-by-year capital reinvestment analysis for Alnylam Pharmaceuticals Inc. See Alnylam Pharmaceuticals Inc financial flexibility index to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 1.06x | $555.87 Million | $524.08 Million | $58.70 Million | ▼ -62.9% |
| 2023 | 2.86x | $297.82 Million | $104.16 Million | $62.21 Million | ▲ +1639.7% |
| 2008 | 0.16x | $10.76 Million | $65.49 Million | $10.76 Million | ▲ +314.7% |
| 2007 | 0.04x | $7.79 Million | $196.52 Million | $7.79 Million | — |